Arvinas’s degrader disappoints
The Pfizer-partnered vepdegestrant shows a benefit in ESR1 mutants, but not in all-comers.
Private biotechs and novel targets head for human trials
Recent first-in-human trials include Pheast and Auron, plus new targets from Immunocore and Cero.
Son of Darzalex hits the skids
J&J decides not to opt in to erzotabart, and Genmab pulls the plug.
J&J catches its menin rivals
The company has caught up with Syndax and overtaken Kura in the first-line menin inhibitor race.
Imfinzi puts its flag on the Matterhorn
A hit on EFS will challenge regulators, and points to Merck's design blunder in Keynote-585.
